Optiver Holding
DNLI icon

Optiver Holding’s Denali Therapeutics DNLI Stock Holding History

Optiver Holding’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20K Sell
776
-90
-10% -$1.85K ﹤0.01% 1524
2026
Q1 		$16.6K Buy
866
+457
+112% +$9.09K ﹤0.01% 1131
2025
Q4 		$6.75K Sell
409
-487
-54% -$8.22K ﹤0.01% 1250
2025
Q3 		$13K Buy
896
+3
+0.3% +$43 ﹤0.01% 1140
2025
Q2 		$12.5K Buy
893
+862
+2,781% +$12.1K ﹤0.01% 945
2025
Q1 		$421 Buy
+31
New +$594 ﹤0.01% 1306

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Optiver Holding's DNLI Position: Q2 2026 in Review

Optiver Holding reduced its Denali Therapeutics (DNLI) stake by 10% in Q2 2026, selling an estimated $1.85K and leaving 776 shares worth $20K. The position accounts for ﹤0.01% of the portfolio, ranked #1524.

Optiver Holding first reported a position in DNLI in Q1 2025 and has held it in 6 quarters since. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • Optiver Holding held 776 shares of Denali Therapeutics worth $20K as of Q2 2026.
  • Optiver Holding sold 90 Denali Therapeutics shares in Q2 2026, an estimated $1.85K.
  • Denali Therapeutics made up ﹤0.01% of Optiver Holding's portfolio in Q2 2026, its #1524 holding.
  • Optiver Holding first reported a position in Denali Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Optiver Holding's 13F filing for Q2 2026, filed 12 Aug 2026.